These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 23053325)

  • 21. Potential for differentiation of glioma recurrence from radionecrosis using integrated
    Sogani SK; Jena A; Taneja S; Gambhir A; Mishra AK; D'Souza MM; Verma SM; Hazari PP; Negi P; Jadhav GK
    Neurol India; 2017; 65(2):293-301. PubMed ID: 28290392
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Suchorska B; Unterrainer M; Biczok A; Sosnova M; Forbrig R; Bartenstein P; Tonn JC; Albert NL; Kreth FW
    J Neurooncol; 2018 Sep; 139(3):721-730. PubMed ID: 29948765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab.
    Harris RJ; Cloughesy TF; Pope WB; Nghiemphu PL; Lai A; Zaw T; Czernin J; Phelps ME; Chen W; Ellingson BM
    Neuro Oncol; 2012 Aug; 14(8):1079-89. PubMed ID: 22711609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ¹⁸F-FLT    and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors.
    Wardak M; Schiepers C; Cloughesy TF; Dahlbom M; Phelps ME; Huang SC
    Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1199-209. PubMed ID: 24604590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment.
    Mehrkens JH; Pöpperl G; Rachinger W; Herms J; Seelos K; Tatsch K; Tonn JC; Kreth FW
    J Neurooncol; 2008 May; 88(1):27-35. PubMed ID: 18217207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of O-(2-
    Verger A; Filss CP; Lohmann P; Stoffels G; Sabel M; Wittsack HJ; Kops ER; Galldiks N; Fink GR; Shah NJ; Langen KJ
    World Neurosurg; 2018 May; 113():e727-e737. PubMed ID: 29510293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.
    Colavolpe C; Chinot O; Metellus P; Mancini J; Barrie M; Bequet-Boucard C; Tabouret E; Mundler O; Figarella-Branger D; Guedj E
    Neuro Oncol; 2012 May; 14(5):649-57. PubMed ID: 22379188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.
    Chen W; Delaloye S; Silverman DH; Geist C; Czernin J; Sayre J; Satyamurthy N; Pope W; Lai A; Phelps ME; Cloughesy T
    J Clin Oncol; 2007 Oct; 25(30):4714-21. PubMed ID: 17947718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.
    Pöpperl G; Goldbrunner R; Gildehaus FJ; Kreth FW; Tanner P; Holtmannspötter M; Tonn JC; Tatsch K
    Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1018-25. PubMed ID: 15877226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors.
    Filss CP; Galldiks N; Stoffels G; Sabel M; Wittsack HJ; Turowski B; Antoch G; Zhang K; Fink GR; Coenen HH; Shah NJ; Herzog H; Langen KJ
    J Nucl Med; 2014 Apr; 55(4):540-5. PubMed ID: 24578243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glioma Recurrence Versus Radiation Necrosis: Single-Session Multiparametric Approach Using Simultaneous O-(2-18F-Fluoroethyl)-L-Tyrosine PET/MRI.
    Jena A; Taneja S; Gambhir A; Mishra AK; Dʼsouza MM; Verma SM; Hazari PP; Negi P; Jhadav GK; Sogani SK
    Clin Nucl Med; 2016 May; 41(5):e228-36. PubMed ID: 26859208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
    Piroth MD; Holy R; Pinkawa M; Stoffels G; Kaiser HJ; Galldiks N; Herzog H; Coenen HH; Eble MJ; Langen KJ
    Radiother Oncol; 2011 May; 99(2):218-24. PubMed ID: 21497925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
    Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma.
    Pöpperl G; Götz C; Rachinger W; Gildehaus FJ; Tonn JC; Tatsch K
    Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1464-70. PubMed ID: 15248032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients.
    Jansen NL; Suchorska B; Wenter V; Eigenbrod S; Schmid-Tannwald C; Zwergal A; Niyazi M; Drexler M; Bartenstein P; Schnell O; Tonn JC; Thon N; Kreth FW; la Fougère C
    J Nucl Med; 2014 Feb; 55(2):198-203. PubMed ID: 24379223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
    Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
    J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma.
    Rapp M; Heinzel A; Galldiks N; Stoffels G; Felsberg J; Ewelt C; Sabel M; Steiger HJ; Reifenberger G; Beez T; Coenen HH; Floeth FW; Langen KJ
    J Nucl Med; 2013 Feb; 54(2):229-35. PubMed ID: 23232275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma.
    Kebir S; Khurshid Z; Gaertner FC; Essler M; Hattingen E; Fimmers R; Scheffler B; Herrlinger U; Bundschuh RA; Glas M
    Oncotarget; 2017 Jan; 8(5):8294-8304. PubMed ID: 28030820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).
    Bashir A; Mathilde Jacobsen S; Mølby Henriksen O; Broholm H; Urup T; Grunnet K; Andrée Larsen V; Møller S; Skjøth-Rasmussen J; Skovgaard Poulsen H; Law I
    Neuro Oncol; 2019 Dec; 21(12):1595-1606. PubMed ID: 31618420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of Bevacizumab on Blood-Brain Barrier Permeability and
    Stegmayr C; Oliveira D; Niemietz N; Willuweit A; Lohmann P; Galldiks N; Shah NJ; Ermert J; Langen KJ
    J Nucl Med; 2017 May; 58(5):700-705. PubMed ID: 28153956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.